drugset / Trial / NCT00890786
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Phase 0
Completed
27 enrolled
Children's Hospital Medical Center, Cincinnati
Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The outcome for children with high-grade gliomas and diffuse intrinsic brainstem gliomas remains poor despite the use of multi-modal therapy with surgery, radiation therapy and chemotherapy.
Timeline
- Start
- 2009-05
- Primary completion
- 2014-10
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Irinotecan | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |